{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T01:24:02Z","timestamp":1781573042056,"version":"3.54.5"},"reference-count":87,"publisher":"Informa UK Limited","issue":"10","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2022,10,3]]},"DOI":"10.1080\/14740338.2022.2134855","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T04:33:53Z","timestamp":1665981233000},"page":"1249-1257","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Drug safety evaluation of ixekizumab for psoriasis: a review of the current knowledge"],"prefix":"10.1080","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4658-7391","authenticated-orcid":false,"given":"Angelo","family":"Ruggiero","sequence":"first","affiliation":[{"name":"University of Naples Federico II","place":["Napoli, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1803-2046","authenticated-orcid":false,"given":"Matteo","family":"Megna","sequence":"additional","affiliation":[{"name":"University of Naples Federico II","place":["Napoli, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Fabbrocini","sequence":"additional","affiliation":[{"name":"University of Naples Federico II","place":["Napoli, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Fornaro","sequence":"additional","affiliation":[{"name":"University of Naples Federico II","place":["Napoli, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Villani","sequence":"additional","affiliation":[{"name":"University of Naples Federico II","place":["Napoli, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,10,31]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10051031"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61128-3"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32549-6"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.07.004"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.23736\/S0392-0488.18.06202-8"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0254-4"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109997"},{"key":"e_1_3_5_10_1","unstructured":"Eli Lilly and Company. Taltz\u00ae (ixekizumab) injection for subcutaneous use: US prescribing information. 2016. [cited 2016 Dec 20]. Avaliable from: http:\/\/www.taltz.com"},{"key":"e_1_3_5_11_1","unstructured":"European Medicines Agency. Taltz\u00ae (ixekizumab): summary of product characteristics. 2015. [cited 2016 Dec 20]. Avaliable from: http:\/\/www.ema.europa.eu"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31946-9"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.04.024"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13756"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.07.048"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.08.046"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.03.047"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512711"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60125-8"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15666"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.2310\/7750.2013.13125"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.04.009"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15879"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/2546161"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-015-0092-3"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2015.1023295"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2016.1132695"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2016.1242409"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S129792"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1559730"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1729736"},{"key":"e_1_3_5_32_1","unstructured":"Preuss CV Quick J. Ixekizumab. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019. [cited 2019 May 5]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK431088\/."},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16050"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.06.153"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14581"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.05.032"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14237"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13990"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028018799982"},{"key":"e_1_3_5_40_1","first-page":"CD01153","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"12","author":"Sbidian E","year":"2017","unstructured":"Sbidian E, Chaimani A, Garcia-Doval I, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2017;12:CD01153.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2019.02.006"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15288"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-019-00490-2"},{"issue":"3","key":"e_1_3_5_44_1","first-page":"581","article-title":"Efficacy and safety of ixekizumab in psoriatic arthritis: a retrospective, single-centre, observational study in a real-life clinical setting","volume":"38","author":"Manfreda V","year":"2020","unstructured":"Manfreda V, Chimenti MS, Canofari C, et al. Efficacy and safety of ixekizumab in psoriatic arthritis: a retrospective, single-centre, observational study in a real-life clinical setting. Clin Exp Rheumatol. 2020 May-Jun;38(3):581\u2013582.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216102"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021.1961998"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100266"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aau8876"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601551"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.12.033"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.021"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0001-7310(14)70016-X"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.09.003"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1709440"},{"key":"e_1_3_5_55_1","first-page":"e15361","article-title":"A case of esophageal candidiasis in a psoriatic patient treated with ixekizumab: should treatment be discontinued?","volume":"8","author":"Ruggiero A","year":"2022","unstructured":"Ruggiero A, Megna M, Marino V, et al. A case of esophageal candidiasis in a psoriatic patient treated with ixekizumab: should treatment be discontinued? Dermatol Ther. 2022 Feb;8:e15361.","journal-title":"Dermatol Ther"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-021-02200-7"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-019-00340-3"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab566"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0612-475"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.01.040"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.10.027"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1159\/000479163"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2016.1228872"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00383-x"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18851"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19509"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19147"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1757605"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2020.109853"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15214"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13839"},{"key":"e_1_3_5_72_1","article-title":"Risk of COVID-19 infection, hospitalization, and mortality in patients with psoriasis treated by interleukin-17 inhibitors [published online ahead of print, 2022 Mar 21]","volume":"33","author":"Kridin K","year":"2022","unstructured":"Kridin K, Schonmann Y, Solomon A, et al. Risk of COVID-19 infection, hospitalization, and mortality in patients with psoriasis treated by interleukin-17 inhibitors [published online ahead of print, 2022 Mar 21]. J Dermatolog Treat. 2022 Jun;33(4):2014\u20132020.","journal-title":"J Dermatolog Treat"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14437"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-04925-8"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4518"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-015-0162-4"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri3707"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5701213"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.399"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1001001"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI40891"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1001153"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.144"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20082767"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16073"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2008.03031.x"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2007.08.006"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1329511"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2016.09.021"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14740338.2022.2134855","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T23:26:06Z","timestamp":1770938766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14740338.2022.2134855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,3]]},"references-count":87,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10,3]]}},"alternative-id":["10.1080\/14740338.2022.2134855"],"URL":"https:\/\/doi.org\/10.1080\/14740338.2022.2134855","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}